These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18275357)

  • 1. Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion.
    Wittlin SD; Marcus AO; Weng CS; Howard CP; Schorr AB;
    Diabetes Technol Ther; 2008 Feb; 10(1):1-10. PubMed ID: 18275357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.
    Weinzimer SA; Ternand C; Howard C; Chang CT; Becker DJ; Laffel LM;
    Diabetes Care; 2008 Feb; 31(2):210-5. PubMed ID: 17989308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.
    Bode B; Weinstein R; Bell D; McGill J; Nadeau D; Raskin P; Davidson J; Henry R; Huang WC; Reinhardt RR
    Diabetes Care; 2002 Mar; 25(3):439-44. PubMed ID: 11874927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients with Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Versus Insulin Aspart.
    Thrasher J; Bhargava A; Rees TM; Wang T; Guzman CB; Glass LC
    Endocr Pract; 2015 Mar; 21(3):247-57. PubMed ID: 25370322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Short acting insulin analogues for treating diabetic patients with CSII (continuous subcutaneous insulin infusion)].
    Jermendy G
    Orv Hetil; 2006 Nov; 147(46):2223-6. PubMed ID: 17396394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
    Bolli GB; Kerr D; Thomas R; Torlone E; Sola-Gazagnes A; Vitacolonna E; Selam JL; Home PD
    Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD; Pellicano F; Scaramuzza A; Sardu C; Casetti T; Bosi E; Miselli V; Brandolini S; Fabbri T; Meandri P; Cannatà F
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.
    Doyle EA; Weinzimer SA; Steffen AT; Ahern JA; Vincent M; Tamborlane WV
    Diabetes Care; 2004 Jul; 27(7):1554-8. PubMed ID: 15220227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.
    Hirsch IB; Bode BW; Garg S; Lane WS; Sussman A; Hu P; Santiago OM; Kolaczynski JW;
    Diabetes Care; 2005 Mar; 28(3):533-8. PubMed ID: 15735183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial.
    van Bon AC; Bode BW; Sert-Langeron C; DeVries JH; Charpentier G
    Diabetes Technol Ther; 2011 Jun; 13(6):607-14. PubMed ID: 21457066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equal metabolic control but superior caregiver treatment satisfaction with insulin aspart in preschool children.
    Pańkowska E; Nazim J; Szalecki M; Urban M
    Diabetes Technol Ther; 2010 May; 12(5):413-8. PubMed ID: 20388052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes.
    Herman WH; Ilag LL; Johnson SL; Martin CL; Sinding J; Al Harthi A; Plunkett CD; LaPorte FB; Burke R; Brown MB; Halter JB; Raskin P
    Diabetes Care; 2005 Jul; 28(7):1568-73. PubMed ID: 15983302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c.
    Retnakaran R; Hochman J; DeVries JH; Hanaire-Broutin H; Heine RJ; Melki V; Zinman B
    Diabetes Care; 2004 Nov; 27(11):2590-6. PubMed ID: 15504991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved blood glucose variability, HbA1c insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter Lispro Insulin Study.
    Johansson UB; Adamson UC; Lins PE; Wredling RA
    Diabetes Metab; 2000 May; 26(3):192-6. PubMed ID: 10880892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump.
    Rubin RR; Peyrot M
    J Diabetes Sci Technol; 2009 Nov; 3(6):1402-10. PubMed ID: 20144395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycemic control and perinatal outcomes of pregnancies complicated by type 1 diabetes: influence of continuous subcutaneous insulin infusion and lispro insulin.
    Chico A; Saigi I; García-Patterson A; Santos MD; Adelantado JM; Ginovart G; de Leiva A; Corcoy R
    Diabetes Technol Ther; 2010 Dec; 12(12):937-45. PubMed ID: 21128840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMPROVED HBA1C, TOTAL DAILY INSULIN DOSE, AND TREATMENT SATISFACTION WITH INSULIN PUMP THERAPY COMPARED TO MULTIPLE DAILY INSULIN INJECTIONS IN PATIENTS WITH TYPE 2 DIABETES IRRESPECTIVE OF BASELINE C-PEPTIDE LEVELS.
    Vigersky RA; Huang S; Cordero TL; Shin J; Lee SW; Chhabra H; Kaufman FR; Cohen O;
    Endocr Pract; 2018 May; 24(5):446-452. PubMed ID: 29847166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.